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Margaret R. Karagas1
It is well-known that UV light exposure and a sun-sensitive phenotype are risk factors for the development of
non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In
this New Hampshire population-based case–control study, we collected data from 5,072 individuals, including
histologically confirmed cases of BCC and SCC, and controls via a personal interview to investigate possible
associations between photosensitizing medication use and NMSC. After adjustment for potentially confounding
factors (e.g., lifetime number of painful sunburns), we found a modest increase in risk of SCC (odds ratio
(OR)¼ 1.2, 95% confidence interval (CI)¼ 1.0–1.4) and BCC (OR¼ 1.2, 95% CI¼ 0.9–1.5), in particular early-onset
BCC, (p50 years of age) (OR¼ 1.5, 95% CI¼ 1.1–2.1) associated with photosensitizing medication use. For SCC the
association was strongest among those with tendency to sunburn rather than tan. We also specifically found
associations with BCC, and especially early-onset BCC, and photosensitizing antimicrobials. In conclusion,
certain commonly prescribed photosensitizing medications may enhance the risk of developing SCC, especially
in individuals with a sun-sensitive phenotype, and may increase the risk of developing BCC and incidence of BCC
at a younger age.
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INTRODUCTION
Non-melanoma skin cancer (NMSC), a designation that
includes both basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC), is the most common type of cancer in
Caucasians. Despite its widespread occurrence, relatively little
is known about the exact incidence of NMSC in the United
States because the population-based cancer surveillance sys-
tems generally do not track NMSC. It is well known that UV
light has a key role in the development of NMSC. Particular
medications that are described as ‘‘photosensitizing,’’ includ-
ing those with known ability to induce either a phototoxic or
photoallergic reaction upon UV exposure, increase the
vulnerability of the skin to UV-induced damage that can lead
to the development of NMSC (Stern, 1998). Such medications
belong to a variety of pharmacological classes by composition
and are used for an array of diverse conditions ranging from
the treatment of acute bacterial infections to long-term
hypertension control (Gould et al., 1995; Bellaney et al.,
1996; Stern, 1998; Epstein, 1999). Photosensitizing medica-
tions, with few exceptions, have not been well-studied with
regard to their long-term damage, such as the later risk of
NMSC. Exceptions include the research regarding oral psoralen
and UV-A light treatment for psoriasis, which was found to
increase the risk of SCC incidence (Stern et al., 1998; Lindelo¨f
et al., 1999). More recently, two record linkage studies from
Denmark and one prospective study from Rotterdam investi-
gated the association between select photosensitizing medica-
tions (namely specific classes of diuretics, antimicrobials, and
retinoids) and NMSC with inconsistent results (Jensen et al.,
2008; Kaae et al., 2010; Ruiter et al., 2010).
In our investigation, as part of the larger New Hampshire
Skin Cancer Study, we conducted a population-based case–
control study that allowed us to obtain detailed information on
major skin cancer risk factors along with history of photo-
sensitizing drug usage to determine whether risks of BCC,
SCC, early-onset BCC (diagnosed at p50 years of age), or
multiple BCC relate to the use of photosensitizing medica-
tions. This current study extends our preliminary work based
on the early phase of our study (Karagas et al., 2007).
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RESULTS
A total of 5,072 participants were eventually enrolled and
interviewed, and responded to questions concerning drug use
during all phases of our study, including 1,906 controls, 1,567
BCC cases, and 1,599 SCC cases. SCC cases were older than
BCC cases, with a slightly higher proportion of men (Table 1).
Both BCC and SCC cases reported having greater skin
sensitivity to the sun than did the controls, and reported a
greater number of lifetime painful sunburns compared with
controls (Table 1). SCC cases had a higher amount of reported
cumulative sun exposure history (Table 1). Tanning lamp use
and medical ionizing radiation exposure were also more
common in cases than controls (Table 1). The majority of
skin tumors were located in the head and neck anatomic
region (Table 1). Additionally, more than 75% of SCC cases
had severe solar elastosis and more than 40% had evidence of
actinic keratoses, in the skin adjacent to the tumor (Table 1).
We found a modest increase in risk of SCC (odds ratio
(OR)¼ 1.2, 95% confidence interval (CI)¼1.0–1.4) and BCC
(OR¼1.2, 95% CI¼0.9–1.5) related to use of photosensitiz-
ing medications, and a 50% greater risk of early-onset BCC
(OR¼1.5, 95% CI¼ 1.1–2.1) (Table 2). Results were similar
in the analysis further restricted to phototoxic medications
(Table 2). For SCC, the association appeared to be largely
among those with a sun-sensitive phenotype (OR¼1.5; 95%
CI 1.1–2.0 for those with a tendency to sunburn, and
OR¼1.0; 95% CI¼0.8–1.3 for those with a tendency to
tan). We did not observe this overall for BCC, but there was a
tendency toward a higher OR among those with a sun-
sensitive phenotype for multiple BCCs (OR¼ 1.7; 95% CI
1.0–3.0 for those with a tendency to sunburn, and OR¼ 1.2;
95% CI¼0.7–2.1 for those with a tendency to tan). We did
not find evidence of modification of risk by other factors we
examined (e.g., by study phase, gender, skin reaction to first
summer sun exposure, history of sunburns, or anatomic site of
the tumor) (data not shown).
We then examined types of photosensitizing medications.
Ever use of photosensitizing antimicrobials was associated
with increased risks of BCC (OR¼1.9, 95% CI¼ 1.3–2.8) and
specifically early-onset BCC (OR¼ 2.1, 95% CI¼1.3–3.5)
(Table 2). These associations were strongest with longer use,
i.e., for 41 year of use for both BCC (OR¼ 1.9, 95%
CI¼ 1.0–3.7) and early-onset BCC (OR¼ 2.0, 95% CI¼0.9–
4.2). In a further division of the antimicrobials, the tetracycline
class of antibiotics was associated BCC (OR¼1.8, 95%
CI¼ 1.2–2.8) and specifically early-onset BCC (OR¼2.0,
95% CI¼ 1.2–3.4) (Table 2), with evidence of a higher risk
with longer duration (P-value for trend based on continuous
duration for BCC¼0.075, and for early-onset BCC¼ 0.03).
The primary reason for treatment was acne and skin rashes,
and within this subgroup associations were present for BCC
and early-onset BCC (BCC OR¼2.6, 95% CI¼1.6–4.2; early-
onset BCC OR¼ 2.3, 95% CI¼1.4–3.9).
We found a modest association between SCC and cardio-
vascular (CV) medication use (OR¼1.3, 95% CI¼ 1.0–1.6)
(Table 2) with evidence of a higher risk with longer duration of
use (OR¼1.4, 95% CI¼1.0–1.8). ORs of SCC were specifi-
cally increased for diuretics (OR¼1.3, 95% CI¼0.9–2.0),
Table 1. Demographics
Controls, N(%) SCC1, N(%) BCC2, N(%)
Phases
Early (1993–2000) 1,043 (54.7) 847 (53.0) 1,110 (70.8)
Late (2001–2009) 863 (45.3) 752 (47.0) 457 (29.2)
Total 1,906 1,599 1,567
Age (years)
o40 155 (8.1) 19 (1.2) 184 (11.7)
41–50 319 (16.7) 114 (7.1) 489 (31.2)
51–60 362 (19.0) 346 (21.6) 297 (19.0)
61–70 728 (38.2) 705 (44.1) 413 (26.4)
70þ 342 (17.9) 415 (26.0) 184 (11.7)
Gender
Male 1,078 (56.6) 987 (61.7) 794 (50.7)
Female 828 (43.4) 612 (38.3) 773 (49.3)
Skin reaction to first hour of sun in summer3
Tan 1,274 (67.2) 908 (57.3) 838 (54.0)
Burn 621 (32.8) 676 (42.7) 713 (46.0)
Lifetime warm month hours sun exposure (0900–1700h)3
p15,676 887 (51.5) 597 (40.6) 896 (61.2)
415,676 836 (48.5) 874 (59.4) 568 (38.8)
Lifetime number of painful sunburns3
0 556 (31.6) 362 (24.3) 369 (25.3)
1–2 451 (25.6) 299 (20.1) 278 (19.1)
3–15 399 (22.6) 369 (24.7) 342 (23.5)
X16 356 (20.2) 461 (30.9) 468 (32.1)
Tanning lamp use3
Never 1,471 (79.9) 1,190 (76.3) 1,066 (70.3)
Ever 369 (20.1) 370 (23.7) 450 (29.7)
Radiation treatment3
Never 1,751 (94.4) 1,390 (89.9) 1,422 (91.9)
Ever 104 (5.6) 157 (10.1) 126 (8.1)
Anatomic site4
Head/neck only 871 (56.5) 888 (59.0)
Other sites only 671 (43.5) 618 (41.0)
Solar elastosis
Absent 6 (0.7) 5 (0.8)
Minimal 39 (4.5) 80 (12.2)
Moderate 162 (18.6) 165 (25.1)
Severe 665 (76.3) 407 (61.9)
Actinic keratoses
Absent 564 (58.9)
Present 394 (41.1)
Abbreviations: BCC; basal cell carcinoma; SCC, squamous cell carcinoma.
1SCC cases and controls from study phases 1 through 4.
2BCC cases and controls from study phases 1 through 3.
3Variables with unknown values include skin reaction to the first hour of
sun exposure in the summer (11 SCC controls and 15 SCC cases, 11 BCC
controls and 16 BCC cases), painful sunburns (144 SCC controls and 108
SCC cases, 127 BCC controls and 110 BCC cases), radiation treatment (51
SCC controls and 52 SCC cases, 15 BCC controls and 19 BCC cases), hours
sun exposure in warm months (183 SCC controls and 128 SCC cases, 141
BCC controls and 103 BCC cases), tanning lamp use (66 SCC controls and
39 SCC cases, 65 BCC controls and 51 BCC cases).
4Anatomic site variables exclude 64 SCC cases with SCC to multiple sites.
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thiazide diuretics (OR¼ 1.3, 95% CI¼ 0.7–2.4), and non-
diuretic CV medications (OR¼1.3, 95% CI¼1.0–1.7). No
relation was found between CV medication use and the risk of
BCC (OR¼ 0.8, 95% CI¼0.5–1.3) (Table 2).
DISCUSSION
Our study of the association between the use of photosen-
sitizing agents and NMSC provides some evidence that
commonly used photosensitizing medications may enhance
the risk of both SCC and BCC. For BCC, associations
were strong for early-onset disease (p50 years) and for SCC
among those with a sun-sensitive phenotype (e.g., tendency to
sunburn).
Although the literature is sparse, as in our study, a study
from Denmark likewise found an association between the use
of tetracyclines and BCC (incidence rate ratio (IRR)¼ 1.3, 95%
CI¼ 1.3–1.4), and additionally found a relation with SCC
(IRR¼1.5, 95% CI¼ 1.4–1.7) (Kaae et al., 2010) that we did
not detect. The study based in Denmark involved linkage
between cancer registry and national pharmacy data, which
limited their ability to assess sun sensitivity or sun exposure as
potentially confounding or modifying factors. One possible
explanation for our finding of an association with BCC but not
SCC is that tetracyclines are commonly used for acne
treatment during the teenage years, a period when UV
exposure has been related to an increased risk of BCC
(Gallagher et al., 1995), whereas chronic UV exposure
appears to more strongly relate to risk of SCC (Armstrong
and Kricker, 2001). In our study, the majority of BCC cases
and controls reported antimicrobial use for acne and other
skin conditions, which raises the possibility that acne or
another form of treatment for acne, such as ionizing
radiation, may be confounding the association between
tetracycline use and BCC. Although acne is not a risk factor
for BCC to our knowledge, there are reported associations
with psoriasis and atopic dermatitis (Frentz and Olsen, 1999;
Olesen et al., 2005). The possibility of confounding by
ionizing radiation treatment used for treatment of acne is
unlikely because its use was uncommon after 1960, and
therefore would not have contributed much to the incidence
of early-onset BCC. Further, adjustment for ionizing radiation
therapy did not appreciably alter our results.
Another category we studied was photosensitizing CV
medications. Although prior studies have investigated this
topic, the results have varied for the different medications. A
recently published USA-based case–control study found
longer durations of use of thiazide diuretics to be associated
with increased ORs for the development of carcinoma of
the lip (Friedman et al., 2012). A case–control study in
Denmark found that users of the diuretic therapy combination
of amiloride and hydrochlorothiazide had an increased
risk of SCC with an IRR of 1.79 (95% CI¼1.45–2.21), but
did not find statistically significant results for other diuretics
or BCC (Jensen et al., 2008). When we restricted our
analysis to thiazide diuretics (i.e., hydrochlorothiazide or
hydrochlorothiazide combination medications), we found a
similar modest association with SCC. A population-based
follow-up study based in the Netherlands found an
association between loop diuretics (e.g., furosemide,
bumetanide) and BCC with a hazard ratio of 1.07 (95%
CI¼ 1.01–1.13) (Ruiter et al., 2010). Another population-
based cohort study from Denmark found a significant
association between methyldopa and BCC, and an asso-
ciation between furosemide and SCC (Kaae et al., 2010).
Table 2. Odds ratios
Controls
SCC cases
Controls
BCC cases
Controls
Early-onset BCC cases
Controls
Multiple BCC cases
N (%) N (%)
OR1
(95% CI) N (%) N (%)
OR1
(95% CI) N (%) N (%)
OR1
(95% CI) N (%) N (%)
OR1
(95% CI)
Photosensitizing medications
No use 1,385 (72.7) 1,062 (66.5) 1.0 (reference) 1,256 (85.2) 1,303 (83.2) 1.0 (reference) 760 (87.8) 514 (76.4) 1.0 (reference) 1,256 (85.2) 181 (71.2) 1.0 (reference)
Ever use 521 (27.3) 536 (33.5) 1.2 (1.0–1.4) 219 (14.8) 264 (16.8) 1.2 (0.9–1.5) 106 (12.2) 159 (23.6) 1.5 (1.1–2.1) 219 (14.8) 74 (28.8) 1.4 (1.0–2.1)
Phototoxic medications
No use 1,385 (75.8) 1,062 (69.9) 1.0 (reference) 1,256 (87.8) 1,303 (86.1) 1.0 (reference) 760 (90.0) 514 (79.3) 1.0 (reference) 1,256 (87.8) 181 (754) 1.0 (reference)
Ever use 441 (24.2) 458 (30.1) 1.1 (0.9–1.4) 174 (12.2) 211 (13.9) 1.1 (0.9–1.5) 84 (10.0) 134 (20.7) 1.5 (1.1–2.1) 174 (12.2) 59 (24.6) 1.4 (0.9–2.1)
Antimicrobial medications
No use 1,385 (96.0) 1,062 (95.2) 1.0 (reference) 1,256 (97.1) 1,303 (93.5) 1.0 (reference) 760 (96.3) 514 (88.5) 1.0 (reference) 1,256 (97.1) 181 (94.3) 1.0 (reference)
Ever use 57 (4.0) 54 (4.8) 1.4 (0.9–2.1) 38 (2.9) 90 (6.5) 1.9 (1.3–2.8) 29 (3.7) 67 (11.5) 2.1 (1.3–3.5) 38 (2.9) 11 (5.7) 1.6 (0.7–3.5)
Tetracyclines
No use 1,385 (97.0) 1,062 (97.3) 1.0 (reference) 1,256 (97.5) 1,303 (94.4) 1.0 (reference) 760 (96.8) 514 (89.5) 1.0 (reference) 1,256 (97.5) 181 (96.3) 1.0 (reference)
Ever use 43 (3.0) 29 (2.7) 1.0 (0.6–1.7) 32 (2.5) 77 (5.6) 1.8 (1.2–2.8) 25 (3.2) 60 (10.5) 2.0 (1.2–3.4) 32 (2.5) 7 (3.7) 1.2 (0.5–2.9)
Cardiovascular medications
No use 1,385 (87.7) 1,062 (81.0) 1.0 (reference) 1,256 (96.2) 1,303 (96.9) 1.0 (reference) 760 (97.9) 514 (96.4) 1.0 (reference) 1,256 (96.2) 181 (91.9) 1.0 (reference)
Ever use 195 (12.3) 249 (19.0) 1.3 (1.0–1.6) 49 (3.8) 41 (3.1) 0.8 (0.5–1.3) 16 (2.1) 19 (3.6) 1.7 (0.8–3.6) 49 (3.8) 16 (8.1) 1.2 (0.6–2.3)
1Adjusted by age, sex, number of painful sunburns, and study phase in final models; other confounder effects including the lifetime hours of warm months sun
exposure, skin response to first hour of sun in summer, tanning lamp use, and radiation treatment did not alter estimates of photosensitizing medications effects
and were not included in final models.
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These findings, along with our own, raise the possibility
of an enhanced NMSC risk with certain CV medications,
specifically diuretics and namely thiazide diuretics that will
need further confirmation.
A major limitation of our study is that we relied on self-
reported medication use. The phrasing of questions differed
between the early and late phases of the study that we
were able to take into account by including a random
effect term for study period. We did not detect any statistically
significant differences between the ORs by study phase.
For our main finding on BCC and antibiotic use, e.g., the
OR in the early phase was 1.96 (95% CI¼ 1.11–3.45) and for
the later phase was 1.83 (95% CI¼1.01–3.32). However, it is
possible that we missed photosensitizing drugs that were
used but not reported by subjects, especially in the early
phase when the question relied on the subject supplying
the name of the medication rather than choosing from a
predetermined list. This misclassification was likely non-
differential and thus could have biased our results toward
the null, as differential misclassification would have resulted
in an increased risk associated with other similar medications
where we observed a reduced risk (e.g., with NSAIDS) (Torti
et al., 2011). Another bias inherent in this study design is
selection bias from non-participation, although it is unlikely
that those who chose not to participate were different in
meaningful ways (e.g., in terms of photosensitizing drug use,
and/or NMSC risk) for the purposes of this study. Controls
were matched to cases on age and sex to represent the
population from which the cases arose. Overall 97% of
cases 65 years of age or older were enrolled in Medicare,
and 96% of cases o65 years held a valid driver’s license.
Additionally, despite our detailed personal interview, we
consider that there could be residual confounding from
unmeasured factors contributing to the modest ORs we
observed. We note however that given the magnitude of the
skin cancer problem worldwide, use of the photosensitizing
agents causing even small increases in the relative risks of
BCCs or SCCs could translate into an appreciable number of
new cases of these malignancies.
One advantage to our approach is that it allowed us to
evaluate several types of medications in a large group of BCC
and SCC cases and controls. The study was population-based
and we had an active surveillance system in place to ensure
that we were informed of new cases during the study period.
To our knowledge, there is limited prior research on these
medications in relation to NMSC in the US population.
Additionally, the personal interview allowed for collection of
demographic information and sun sensitivity (i.e., propensity
to tan or burn), cumulative lifetime sun exposure, indication
for use, and prior radiation treatment, among others. As
expected, we observed stronger associations among those
with a sun-sensitive phenotype for SCC and to a lesser extent
multiple BCCs, which is consistent with a finding reported
from the Rotterdam cohort study for BCC (Ruiter et al., 2010).
As to why our findings were stronger for early-onset BCC is
unclear, but may relate to the fact that antibiotics used to treat
acne are taken at a young age. Further studies will need to
evaluate this possibility.
In conclusion, we found evidence that use of certain
photosensitizing medications may enhance risks of SCC and
BCC in the US population, particularly among individuals
with a sun-sensitive phenotype, and for BCC, those with a
young age at onset.
MATERIALS AND METHODS
Study group
The cases for our study were identified by obtaining records of SCC
and BCC diagnoses from dermatology, dermatopathology, and
pathology practices throughout the state of NH that were histologi-
cally confirmed. To be eligible, cases and controls needed to be
residents of New Hampshire, speak English, have a listed telephone
number, and between the ages of 25 and 74 at the time of diagnosis
(or for controls a matched ‘‘reference date’’). During all periods: July
1993 through June 1995, July 1997 through March 2000, July 2001
through June 2002, and July 2007 through June 2009, we selected all
eligible cases of invasive SCC that met our inclusion criteria. A total of
4,026 cases were contacted, of which 3,242 (81%) took part, for a
total of 1,637 cases of SCC and 1,605 cases of BCC. During the first
period, we sampled an approximately two-to-one ratio of BCC to
SCC, and in the second period approximately a one-to-one ratio of
BCC to SCC. In the third period, we selected all cases diagnosed
before the age of 51 years (‘‘early-onset’’), or with multiple con-
comitant BCCs. Cases included NMSC diagnoses from all anatomic
sites excluding genital cancers.
The control subjects for our study were frequency matched, to
the combined distribution of NMSC cases, in each study period, on
age and sex from population lists of New Hampshire residents ages
25–74 years of age. Controls younger than 65 years of age were
chosen from a list of New Hampshire residents provided by the
New Hampshire Department of Transportation, while controls
65 years of age and older were chosen from New Hampshire
residents enrolled in the Center for Medicare and Medicaid Services.
These control subjects were selected to match our cases by age and
sex stratification. A total of 2,797 controls were contacted of which
1,952 (70%) enrolled.
Interview
Written informed consent was obtained from each participant in
accordance with Committee for the Protection of Human Subjects
at Dartmouth College, Hanover, NH, and the Declaration of
Helsinki Principles. The personal interviews, which were usually
conducted at the home of the subject, took place between
February 1994 and June 2011. The interview included collection of
information regarding skin sensitivity upon acute exposure to the sun
(i.e., whether the respondent’s skin would tan or burn after first
exposure to the sun in summer for 1 hour), lifetime number of painful
or blistering sunburns, lifetime sun exposure (during warm months
between 0900 and 1700 hours, as well as during cool months),
history of treatment involving radiation, and ever use of a tanning
device. The interviewers were not aware of the case–control status
of participants.
Determination of drug usage
During the first two recruitment periods (the ‘‘early phase’’), we asked
whether participants had used any medications that made their skin
unusually sensitive to the sun. We then asked them to name the
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medication, the reason for use and duration of use. From this
information, we coded any drugs that are known to have photo-
sensitizing properties, based on a list compiled from a search of the
literature (Gould et al., 1995; Bellaney et al., 1996; Stern, 1998;
Epstein, 1999). After exclusion of the drugs without photosensitizing
properties and the few that were not recognizable as drug names, we
restricted the data to include only drugs used for duration of one
month or longer.
During the last two recruitment periods (the ‘‘late phase’’)
drug usage information was collected based on selection of
medications by the participant from a prompted list of known
photosensitizing medications, as well as other medications by
category such as antibiotic, heart medication (e.g., antihypertensives),
anti-anxiety medication, retinoid, chemotherapeutic, and pain
mediation (e.g., NSAIDs). We restricted the duration of use of the
drug to a minimum of 6 months and there was a minimum frequency
of use of four times per week. Table 3 presents a summary of the
frequency of use of reported medications across the entire study
population.
Statistical analysis
We computed ORs and their 95% confidence intervals for all
SCC, BCC, early-onset BCC, and multiple BCC case groups for
the studied drugs using logistic regression with those who responded
that they did not ever use the photosensitizing medications as
the reference category. To adjust for potentially confounding
factors, skin response to first hour of sun exposure in summer (tan
or mild burn followed by a tan, painful burn or burn with blistering),
lifelong cumulative number of hours of sun exposure (pmedian hours
exposure, 4median hours exposure), tanning device use, radiation
treatment for conditions other than skin cancer, anatomic site, the
histologic presence of actinic keratosis (SCC only), and the
histologic presence of solar elastosis were all included in preliminary
models. But the inclusion of these variables did not appreciably
influence our results and therefore were not included in our
final models. Subjects with missing covariates were omitted from
the multivariate analysis. All final model risk estimates were
adjusted by age, sex, and number of previous painful sunburns
(none, 1–2, 3–15, and 415). Because of differences in the ques-
tionnaires between the early phase (1993–2000) and late phase
(2001–2009), we included study phase as a random strata effect in
all of our models (Derr, 2000; Kuss, 2002). We assessed the
potential modifying effects of sex, study phase, and UV-related
factors (e.g., skin sensitivity to the sun exposure in summer and
by lifetime number of painful sunburns), we computed ORs stratified
by these factors.
We also examined duration of photosensitizing medication use
(classified into non-users, 41 month but o7 years, and X7 years
overall, and non-user, p1 year of use, 41 year of use for specific
mediations). Tests for trend were performed by modeling duration as
a continuous variable in months of medication use (P-value for trend
continuous).
Pharmacological class was used to evaluate conditions for
which drugs were being use. Additionally we analyzed specific
conditions for which antimicrobials were used. Self-reported
conditions were categorized into: (1) acne and other skin rashes,
(2) non-skin infections, and (3) arthritis (both rheumatoid and
not otherwise specified) allowing analysis of photosensitizing
medication risk in these subgroups of antibiotic use. In addition to
evaluating subgroups of tumors separately (SCC, BCC, and for
BCC early-onset and BCC multiple tumors), we further analyzed
subgroups of tumors according to the presence or absence of
actinic keratosis (SCC only), and the presence or absence of solar
elastosis in the adjacent skin, as well as the anatomic site of the
skin lesions. The statistical package SAS version 9.2 (SAS Institute,
Cary, NC) was used for all the analyses.
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Table 3. Frequency of use of photosensitizing
medications for total study population listed by
pharmacological class
Drug type Frequency1
Antimicrobials
Tetracyclines (e.g., tetracycline, doxycycline)2 123
Sulfonamide antibiotics (e.g., trimethoprim/
sulfamethoxazole)2
47
Fluroquinolones (e.g., ciprofloxacin)2 7
Cardiovascular
Antihypertensives
Thiazides (e.g., hydrochlorothiazide, including
combination medication such as hydrochlorothiazide/
triamterene)2
239
Loop diuretics (e.g., furosemide)2 46
Calcium channel blockers (e.g., diltiazem2, nifedipine) 44
Potassium-sparing diuretics (e.g., triamterene) 29
Alpha-adrenergic agonists (e.g., methyldopa) 3
Other
Antiarrhythmics (e.g., amiodarone, quinidine)2 11
Sulfonylureas (e.g., glipizide, glyburide) 3
Chemotherapeutics
Antimetabolite (e.g., methotrexate)2 8
Antiestrogen (e.g., tamoxifen)2 6
Nonsteroidal anti-inflammatory drugs
Salicylic acid derivatives (e.g., acetylsalicylic acid)2 623
Proprionic acid derivatives (e.g., ibuprofen, naproxen)2 432
Acetic acid derivatives (e.g., nabumetone)2 4
Enolic acid derivatives (e.g., piroxicam) 4
Psychiatric medications
Benzodiazepines (e.g., alprazolam, diazepam) 112
Tricyclic antidepressants (e.g., amitriptyline) 13
Retinoids
Topical (e.g., tretinoin)2 72
Oral (e.g., isotretinoin)2 12
1Photosensitizing medications were not listed in this table if only one or
fewer usages.
2In addition to being photosensitizing, these drugs are also classified as
having phototoxic effects.
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